NCT02366884: Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis

NCT02366884
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02366884

Comments are closed.

Up ↑